

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
10/005.921	12/04/2001	Keith D. Allen	R-714

DELTAGEN, INC. 740 Bay Road Redwood City, CA 94063 CONFIRMATION NO. 7082
WITHDRAWAL NOTICE

OC000000008309449

Date Mailed: 06/19/2002

WITHDRAWAL OF PREVIOUSLY SENT NOTICE

The Notice mailed on 04/29/2002 was sent in error and is hereby withdrawn. A corrected Notice is enclosed. The time period for reply runs from the mail date of the corrected Notice. We apologize for any inconvenience this caused.

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 3 - OFFICE COPY

APPLICATION 10/005921 DOES NOT COMPLY WITH THE SEQUENCE RULES BECAUSE:

	CRF, paper copy of sequence listing, and statement that both are same are missing
	CRF contains error(s) according to STIC Report
·	CRF damaged or unreadable according to STIC Report
X	Other: Figure 2A contains a nucleic acid sequence that is not described in the sequence listing or CRF. If it is described in the CRF, a SEQ ID NO is required in the description or drawing.



United States Patent and Trademark Office

COMMISSIONER FOI UNITED STATES PATENT AND TRADEMAR WASHINGTON, D

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

10/005,921

12/04/2001

Keith D. Allen

R-714

DELTAGEN, INC. 740 Bay Road Redwood City, CA 94063

CONFIRMATION NO. 7082 FORMALITIES LETTER *OC000000008309455*

Date Mailed: 06/19/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821 - 1.825. The application must be in sequence compliance before examination on the merits.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. §§ 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extension of time may be obtained by filing a petition accompanier by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to: The Office Of Initial Patent Examination.

See the attachment.

Applicant Must Provide as part of the response:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600

 For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 3 – OFFICE COPY